Cargando…

Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

BACKGROUND: To develop guidelines and recommendations to prevent and treat glucocorticoid (GC)-induced osteoporosis (GIOP) in Korea. METHODS: The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology have developed this guideline based on Guidance for the Development of...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, So Young, Gong, Hyun Sik, Kim, Kyoung Min, Kim, Dam, Kim, Ha Young, Jeon, Chan Hong, Ju, Ji Hyeon, Lee, Shin-Seok, Park, Dong-Ah, Sung, Yoon-Kyoung, Kim, Sang Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society for Bone and Mineral Research 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288607/
https://www.ncbi.nlm.nih.gov/pubmed/30574464
http://dx.doi.org/10.11005/jbm.2018.25.4.195
_version_ 1783379830804316160
author Park, So Young
Gong, Hyun Sik
Kim, Kyoung Min
Kim, Dam
Kim, Ha Young
Jeon, Chan Hong
Ju, Ji Hyeon
Lee, Shin-Seok
Park, Dong-Ah
Sung, Yoon-Kyoung
Kim, Sang Wan
author_facet Park, So Young
Gong, Hyun Sik
Kim, Kyoung Min
Kim, Dam
Kim, Ha Young
Jeon, Chan Hong
Ju, Ji Hyeon
Lee, Shin-Seok
Park, Dong-Ah
Sung, Yoon-Kyoung
Kim, Sang Wan
author_sort Park, So Young
collection PubMed
description BACKGROUND: To develop guidelines and recommendations to prevent and treat glucocorticoid (GC)-induced osteoporosis (GIOP) in Korea. METHODS: The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology have developed this guideline based on Guidance for the Development of Clinical Practice Guidelines ver. 1.0 established by the National Evidence-Based Healthcare Collaborating Agency. This guideline was developed by adapting previously published guidelines, and a systematic review and quality assessment were performed. RESULTS: This guideline applies to adults aged ≥19 years who are using or plan to use GCs. It does not include children and adolescents. An initial assessment of fracture risk should be performed within 6 months of initial GC use. Fracture risk should be estimated using the fracture-risk assessment tool (FRAX) after adjustments for GC dose, history of osteoporotic fractures, and bone mineral density (BMD) results. All patients administered with prednisolone or an equivalent medication at a dose ≥2.5 mg/day for ≥3 months are recommended to use adequate calcium and vitamin D during treatment. Patients showing a moderate-to-high fracture risk should be treated with additional medication for osteoporosis. All patients continuing GC therapy should undergo annual BMD testing, vertebral X-ray, and fracture risk assessment using FRAX. When treatment failure is suspected, switching to another drug should be considered. CONCLUSIONS: This guideline is intended to guide clinicians in the prevention and treatment of GIOP.
format Online
Article
Text
id pubmed-6288607
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Society for Bone and Mineral Research
record_format MEDLINE/PubMed
spelling pubmed-62886072018-12-20 Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis Park, So Young Gong, Hyun Sik Kim, Kyoung Min Kim, Dam Kim, Ha Young Jeon, Chan Hong Ju, Ji Hyeon Lee, Shin-Seok Park, Dong-Ah Sung, Yoon-Kyoung Kim, Sang Wan J Bone Metab Guideline BACKGROUND: To develop guidelines and recommendations to prevent and treat glucocorticoid (GC)-induced osteoporosis (GIOP) in Korea. METHODS: The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology have developed this guideline based on Guidance for the Development of Clinical Practice Guidelines ver. 1.0 established by the National Evidence-Based Healthcare Collaborating Agency. This guideline was developed by adapting previously published guidelines, and a systematic review and quality assessment were performed. RESULTS: This guideline applies to adults aged ≥19 years who are using or plan to use GCs. It does not include children and adolescents. An initial assessment of fracture risk should be performed within 6 months of initial GC use. Fracture risk should be estimated using the fracture-risk assessment tool (FRAX) after adjustments for GC dose, history of osteoporotic fractures, and bone mineral density (BMD) results. All patients administered with prednisolone or an equivalent medication at a dose ≥2.5 mg/day for ≥3 months are recommended to use adequate calcium and vitamin D during treatment. Patients showing a moderate-to-high fracture risk should be treated with additional medication for osteoporosis. All patients continuing GC therapy should undergo annual BMD testing, vertebral X-ray, and fracture risk assessment using FRAX. When treatment failure is suspected, switching to another drug should be considered. CONCLUSIONS: This guideline is intended to guide clinicians in the prevention and treatment of GIOP. The Korean Society for Bone and Mineral Research 2018-11 2018-11-30 /pmc/articles/PMC6288607/ /pubmed/30574464 http://dx.doi.org/10.11005/jbm.2018.25.4.195 Text en Copyright © 2018 The Korean Society for Bone and Mineral Research http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Guideline
Park, So Young
Gong, Hyun Sik
Kim, Kyoung Min
Kim, Dam
Kim, Ha Young
Jeon, Chan Hong
Ju, Ji Hyeon
Lee, Shin-Seok
Park, Dong-Ah
Sung, Yoon-Kyoung
Kim, Sang Wan
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title_full Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title_fullStr Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title_full_unstemmed Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title_short Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
title_sort korean guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
topic Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288607/
https://www.ncbi.nlm.nih.gov/pubmed/30574464
http://dx.doi.org/10.11005/jbm.2018.25.4.195
work_keys_str_mv AT parksoyoung koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT gonghyunsik koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT kimkyoungmin koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT kimdam koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT kimhayoung koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT jeonchanhong koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT jujihyeon koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT leeshinseok koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT parkdongah koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT sungyoonkyoung koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis
AT kimsangwan koreanguidelineforthepreventionandtreatmentofglucocorticoidinducedosteoporosis